Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2008 Jul 7;7(7):1871–1879. doi: 10.1158/1535-7163.MCT-08-0308

Figure 1.

Figure 1

The combination of ranpirnase and rosiglitazone increased cytotoxicity after 48 h of treatment compared to ranpirnase or rosiglitazone alone in seven of twelve human cancer cell lines in vitro as determined by the MTS viability assay test. A. T47D. B. MCF7. C. 231. D. LNCaP. E. DU-145. F. PC3. G. SKOV-3. H. CAOV-3. I. MP5. J. MP2. K. H292. L. H1792. C = medium only control; Onc 1 = ranpirnase 1 μg/mL; Rosi20 = rosiglitazone 20 μM; O+R = both. Bars represent mean fold changes ± SEM of 8 samples per group. Experiments repeated twice. * = P ≤ 0.05 in comparison to control; ! = P ≤ 0.05 in comparison to both single treatments.